Module 4 – Case Study 5 Pharmacometrics & QSP-Based Analysis to Guide GnRH Receptor Modulator Dev’t.

Автор: U.S. Food and Drug Administration

Загружено: 2024-08-01

Просмотров: 450

Описание:

Dr. Adekemi Taylor, Senior Director of Integrated Drug Development at Certara, discusses model interconnectedness and how modeling was used to guide development of a gonadotropin-releasing hormone receptor for the treatment of endometriosis.

This module is part of the educational series “Model-Informed Drug Development (MIDD): Methods Advancing Medical Products to Patients”. The educational content was developed for regulatory scientists by experts in the field in partnership with the Critical Path Institute and funded by FDA CDER Office of Translational Sciences. As part of Multidisciplinary Education and Exchange initiatives, CDER’s Quantitative Medicine Center of Excellence is making this resource accessible to all, supporting community-wide educational enrichment.

Disclaimer: The presentations in this educational series reflect the views of the presenters and should not be construed to represent FDA’s views or policies.

Module 4 – Case Study 5 Pharmacometrics & QSP-Based Analysis to Guide GnRH Receptor Modulator Dev’t.

Доступные форматы для скачивания:

Скачать видео mp4

Информация по загрузке:

Скачать аудио mp3

Похожие видео

Module 4 - Case Study 6: Role of Modeling & Simulation in the Development of Pembrolizumab

Module 4 - Case Study 6: Role of Modeling & Simulation in the Development of Pembrolizumab

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Risk Management

Module 8 – Part 6: Artificial Intelligence (AI) & Machine Learning (ML) in MIDD

Module 8 – Part 6: Artificial Intelligence (AI) & Machine Learning (ML) in MIDD

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

Introduction to the MIDD Training Course

Introduction to the MIDD Training Course

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Direct: Catching Up on Agency Reforms

FDA Direct: Catching Up on Agency Reforms

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Direct: FDA Awards Six National Priority Vouchers

FDA Direct: FDA Awards Six National Priority Vouchers

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S05 - (PV): Future of...

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S05 - (PV): Future of...

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Public Meeting: Reauthorization of the Biosimilar User Fee Act

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

2025 FDA Achievements

2025 FDA Achievements

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025